Total Payments
$488.30
2019 Payments
$44.19
Companies
7
Transactions
26
Medicare Patients
10,944
Medicare Billing
$417,022
Payment Breakdown by Category
Food & Beverage$488.30 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $488.30 | 26 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $215.84 | 12 | $0 (2019) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $93.08 | 5 | $0 (2018) |
| Celgene Corporation | $65.94 | 3 | $0 (2017) |
| Incyte Corporation | $58.15 | 3 | $0 (2018) |
| Millennium Pharmaceuticals, Inc. | $24.14 | 1 | $0 (2017) |
| Otsuka America Pharmaceutical, Inc. | $19.35 | 1 | $0 (2017) |
| AstraZeneca Pharmaceuticals LP | $11.80 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2019 | $44.19 | 2 | E.R. Squibb & Sons, L.L.C. ($44.19) |
| 2018 | $93.88 | 5 | Boehringer Ingelheim Pharmaceuticals, Inc. ($40.04) |
| 2017 | $350.23 | 19 | E.R. Squibb & Sons, L.L.C. ($135.96) |
All Payment Transactions
26 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/20/2019 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $22.76 | General |
| 06/21/2019 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $21.43 | General |
| 05/18/2018 | E.R. Squibb & Sons, L.L.C. | EMPLICITI (Biological) | Food and Beverage | Cash or cash equivalent | $15.00 | General |
| Category: Oncology | ||||||
| 04/13/2018 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $18.15 | General |
| Category: Hematology/Oncology | ||||||
| 03/16/2018 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $20.69 | General |
| Category: Oncology | ||||||
| 02/23/2018 | Boehringer Ingelheim Pharmaceuticals, Inc. | GILOTRIF (Drug) | Food and Beverage | In-kind items and services | $23.41 | General |
| Category: ONCOLOGY | ||||||
| 01/09/2018 | Boehringer Ingelheim Pharmaceuticals, Inc. | GILOTRIF (Drug) | Food and Beverage | In-kind items and services | $16.63 | General |
| Category: ONCOLOGY | ||||||
| 12/01/2017 | Millennium Pharmaceuticals, Inc. | NINLARO (Drug) | Food and Beverage | In-kind items and services | $24.14 | General |
| Category: Oncology | ||||||
| 11/21/2017 | Boehringer Ingelheim Pharmaceuticals, Inc. | GILOTRIF (Drug) | Food and Beverage | In-kind items and services | $14.97 | General |
| Category: ONCOLOGY | ||||||
| 11/17/2017 | E.R. Squibb & Sons, L.L.C. | EMPLICITI (Biological) | Food and Beverage | Cash or cash equivalent | $16.50 | General |
| Category: Oncology | ||||||
| 11/03/2017 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $20.00 | General |
| Category: Hematology/Oncology | ||||||
| 10/19/2017 | Celgene Corporation | Abraxane (Drug) | Food and Beverage | In-kind items and services | $21.39 | General |
| Category: Oncology | ||||||
| 10/06/2017 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $20.00 | General |
| Category: Hematology/Oncology | ||||||
| 09/01/2017 | Celgene Corporation | Revlimid (Drug) | Food and Beverage | In-kind items and services | $19.69 | General |
| Category: Hematology / Oncology | ||||||
| 08/29/2017 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $11.80 | General |
| Category: Oncology | ||||||
| 08/25/2017 | Boehringer Ingelheim Pharmaceuticals, Inc. | GILOTRIF (Drug) | Food and Beverage | In-kind items and services | $18.10 | General |
| Category: ONCOLOGY | ||||||
| 08/18/2017 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $20.62 | General |
| Category: Oncology | ||||||
| 06/30/2017 | Boehringer Ingelheim Pharmaceuticals, Inc. | GILOTRIF (Drug) | Food and Beverage | In-kind items and services | $19.97 | General |
| Category: ONCOLOGY | ||||||
| 06/09/2017 | E.R. Squibb & Sons, L.L.C. | EMPLICITI (Biological) | Food and Beverage | Cash or cash equivalent | $13.63 | General |
| Category: Oncology | ||||||
| 06/07/2017 | Celgene Corporation | Abraxane (Drug) | Food and Beverage | In-kind items and services | $24.86 | General |
| Category: Oncology | ||||||
| 05/19/2017 | E.R. Squibb & Sons, L.L.C. | EMPLICITI (Biological) | Food and Beverage | Cash or cash equivalent | $16.50 | General |
| Category: Oncology | ||||||
| 05/05/2017 | Otsuka America Pharmaceutical, Inc. | SPRYCEL (Drug) | Food and Beverage | In-kind items and services | $19.35 | General |
| Category: HEMATOLOGY | ||||||
| 04/21/2017 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $16.92 | General |
| Category: Oncology | ||||||
| 03/24/2017 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $17.50 | General |
| Category: Oncology | ||||||
| 03/17/2017 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $17.37 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 28 | 1,693 | 1,721 | $270,995 | $81,395 |
| 2022 | 35 | 3,376 | 3,415 | $365,882 | $119,988 |
| 2021 | 52 | 2,783 | 2,855 | $289,319 | $103,641 |
| 2020 | 49 | 3,092 | 3,227 | $345,216 | $111,998 |
Total Patients
10,944
Total Services
11,218
Medicare Billing
$417,022
Procedure Codes
182
All Medicare Procedures & Services
182 procedure records from CMS Medicare Utilization — Page 1 of 8
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 77067 | Screening mammography | Office | 2023 | 139 | 141 | $58,760 | $18,566 | 31.6% |
| 77067 | Screening mammography | Facility | 2023 | 281 | 281 | $27,257 | $10,327 | 37.9% |
| 77063 | Screening 3d breast mammography | Facility | 2023 | 281 | 281 | $21,637 | $8,205 | 37.9% |
| 77063 | Screening 3d breast mammography | Office | 2023 | 139 | 141 | $19,482 | $7,561 | 38.8% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Facility | 2023 | 42 | 43 | $12,986 | $3,602 | 27.7% |
| 70551 | Mri scan of brain without contrast | Facility | 2023 | 55 | 56 | $10,416 | $2,972 | 28.5% |
| 71250 | Ct scan of chest without contrast | Office | 2023 | 21 | 21 | $14,994 | $2,334 | 15.6% |
| 77080 | Dxa bone density measurement of hip, pelvis, spine | Office | 2023 | 54 | 54 | $13,284 | $2,147 | 16.2% |
| 76536 | Ultrasound scan of head and neck soft tissue | Office | 2023 | 23 | 23 | $7,337 | $2,058 | 28.0% |
| 71046 | X-ray of chest, 2 views | Office | 2023 | 72 | 72 | $6,058 | $1,921 | 31.7% |
| 74176 | Ct scan of abdomen and pelvis without contrast | Office | 2023 | 12 | 12 | $7,596 | $1,733 | 22.8% |
| 73564 | X-ray of knee, 4 or more views | Office | 2023 | 28 | 28 | $4,256 | $1,486 | 34.9% |
| 70553 | Mri scan of brain before and after contrast | Facility | 2023 | 17 | 17 | $4,947 | $1,411 | 28.5% |
| 72110 | X-ray of lower and sacral spine, minimum of 4 views | Office | 2023 | 31 | 31 | $4,309 | $1,333 | 30.9% |
| 76705 | Limited ultrasound scan of abdomen | Office | 2023 | 18 | 18 | $5,094 | $1,327 | 26.1% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Facility | 2023 | 17 | 17 | $3,927 | $1,163 | 29.6% |
| 77065 | Diagnostic mammography of 1 breast | Facility | 2023 | 43 | 46 | $4,738 | $1,152 | 24.3% |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | Facility | 2023 | 52 | 53 | $7,045 | $1,042 | 14.8% |
| 71260 | Ct scan of chest with contrast | Facility | 2023 | 23 | 23 | $3,404 | $1,009 | 29.6% |
| 71275 | Ct scan of blood vessels of chest with contrast | Facility | 2023 | 13 | 13 | $2,990 | $853.69 | 28.6% |
| 76642 | Limited ultrasound scan of 1 breast | Office | 2023 | 12 | 12 | $2,371 | $844.38 | 35.6% |
| 73030 | X-ray of shoulder, minimum of 2 views | Office | 2023 | 25 | 27 | $2,460 | $844.06 | 34.3% |
| 73502 | X-ray of hip, 2-3 views | Office | 2023 | 21 | 21 | $2,520 | $827.19 | 32.8% |
| 76642 | Limited ultrasound scan of 1 breast | Facility | 2023 | 34 | 34 | $3,045 | $819.60 | 26.9% |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | Office | 2023 | 17 | 17 | $1,229 | $742.22 | 60.4% |
About Dr. Milliam Kataoka, MD
Dr. Milliam Kataoka, MD is a Body Imaging healthcare provider based in Northampton, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/16/2009. The National Provider Identifier (NPI) number assigned to this provider is 1295976504.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Milliam Kataoka, MD has received a total of $488.30 in payments from pharmaceutical and medical device companies, with $44.19 received in 2019. These payments were reported across 26 transactions from 7 companies. The most common payment nature is "Food and Beverage" ($488.30).
As a Medicare-enrolled provider, Kataoka has provided services to 10,944 Medicare beneficiaries, totaling 11,218 services with total Medicare billing of $417,022. Data is available for 4 years (2020–2023), covering 182 distinct procedure/service records.
Ad
Practice Information
- Specialty Body Imaging
- Location Northampton, MA
- Active Since 03/16/2009
- Last Updated 01/15/2018
- Taxonomy Code 2085B0100X
- Entity Type Individual
- NPI Number 1295976504
Products in Payments
- OPDIVO (Biological) $110.02
- GILOTRIF (Drug) $93.08
- EMPLICITI (Biological) $61.63
- JAKAFI (Drug) $58.15
- Abraxane (Drug) $46.25
- NINLARO (Drug) $24.14
- Revlimid (Drug) $19.69
- SPRYCEL (Drug) $19.35
- TAGRISSO (Drug) $11.80
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.